Not yet recruitingPHASE1, PHASE2NCT06735820
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
Studying Malignant peripheral nerve sheath tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AeRang Kim
- Principal Investigator
- AeRang Kim, MD, PhD, M.DChildren's National Research Institute
- Intervention
- APG-115(drug)
- Enrollment
- 45 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (1)
- Children's National Hospital, Washington D.C., District of Columbia, United States
Collaborators
Children's National Research Institute
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06735820 on ClinicalTrials.govOther trials for Malignant peripheral nerve sheath tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT06693284A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]University of Minnesota
- RECRUITINGPHASE2NCT04872543A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)Memorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT04222413Metarrestin (ML-246) in Subjects With Metastatic Solid TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT03872427Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN StudyNational Cancer Institute (NCI)
- RECRUITINGNANCT03141021Multi-Institutional Registry for Malignant Peripheral Nerve Sheath TumorsWashington University School of Medicine
See all trials for Malignant peripheral nerve sheath tumor →